Trisomy 15 (mosaic)

Overview

Mosaic trisomy 15 represents a chromosomal abnormality characterised by the presence of an additional copy of chromosome 15 in a proportion of the body's cells, whilst other cells maintain the typical chromosome count. This pattern, termed mosaicism, arises from errors during cell division after fertilisation rather than being inherited from parents. The condition occurs sporadically, meaning it happens by chance and is not passed down through families in a predictable manner.

The clinical presentation of mosaic trisomy 15 varies considerably between affected individuals, largely depending on what percentage of cells carry the extra chromosome and which tissues harbour the abnormal cell line. Some people with low-level mosaicism may experience relatively mild effects, whilst those with higher proportions of trisomic cells typically face more significant developmental and medical challenges. Many cases are initially detected during routine pregnancy screening when ultrasound findings prompt further chromosomal testing, though the condition can also be diagnosed after birth when growth or developmental concerns emerge.

Complete trisomy 15, where all cells contain three copies of chromosome 15, is generally incompatible with survival to term. Mosaic forms, where only some cells are affected, are thus the only viable presentations of trisomy 15 seen in liveborn children and adults. The rarity of this condition means that exact prevalence figures are not well established, though confined placental mosaicism involving chromosome 15 is encountered more frequently during prenatal diagnosis than true foetal mosaicism.

Symptoms & clinical features

The clinical features of mosaic trisomy 15 demonstrate substantial variability, reflecting the unpredictable distribution of trisomic cells across different body systems. Growth difficulties represent one of the most consistent findings, with many affected individuals experiencing intrauterine growth restriction before birth and postnatal growth delay continuing through childhood. Short stature relative to family expectations is commonly observed, alongside feeding difficulties during infancy that may require specialised nutritional support.

Developmental delays affecting motor skills and speech are frequently reported, though intellectual ability spans a wide spectrum. Some children reach developmental milestones within or close to the typical range, whilst others require ongoing educational support and therapeutic interventions. Physical features that may be present include asymmetry of the body or limbs, subtle facial characteristics, and occasional skeletal abnormalities. Heart defects occur in a subset of cases, as do kidney and urinary tract anomalies, though not all individuals develop structural problems with internal organs.

Neurological manifestations can include low muscle tone during infancy, coordination difficulties, and in some instances seizures. Behavioural and learning challenges may emerge during childhood, though these are not universal. The wide phenotypic range means that predicting outcomes for any individual based solely on the chromosomal finding remains challenging, particularly when the level of mosaicism detected in prenatal samples or blood may not accurately reflect the situation in other tissues such as brain or heart.

Video: Genetics 101

Affected organs

Mosaic trisomy 15 can potentially affect multiple organ systems, though the pattern and severity vary considerably between individuals. Growth and skeletal development are commonly impacted, with effects ranging from mild short stature to more pronounced growth restriction requiring endocrinological assessment. The musculoskeletal system may show asymmetry, with one side of the body or particular limbs being smaller or larger than expected, a feature sometimes termed hemihyperplasia when overgrowth is present.

The cardiovascular system is affected in a subset of cases, with structural heart defects including septal defects or valve abnormalities identified in some individuals. Renal and urinary tract development may be disrupted, leading to kidney malformations or functional concerns that warrant monitoring. The central nervous system can be impacted in ways that affect cognitive development, muscle tone, and coordination, though brain imaging does not always reveal structural abnormalities even when developmental delays are present. The endocrine system may be involved, with some individuals experiencing growth hormone deficiency or other hormonal imbalances that influence growth and development.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The severity of mosaic trisomy 15 exists on a continuum, influenced primarily by the proportion of cells carrying the extra chromosome and which tissues are affected. Individuals with low-level mosaicism confined largely to blood cells may experience minimal clinical effects, whilst those with higher levels of mosaicism across multiple tissues typically face more significant developmental and medical challenges. This variability makes prognostication difficult, particularly when the condition is detected prenatally and the full extent of tissue involvement cannot be determined until after birth.

Lifetime health risks depend on which organ systems are affected. Those with structural heart defects require cardiology follow-up and may need surgical intervention during childhood. Growth delays often persist throughout development, with final adult height typically below average for family background. Learning difficulties and developmental delays, when present, generally require ongoing educational support, though many affected individuals achieve functional independence as adults. Seizure disorders, when they occur, typically require neurological management with anticonvulsant therapy where indicated by specialist assessment.

Age of onset for recognising clinical features varies. Intrauterine growth restriction may be evident on antenatal ultrasound scans during the second or third trimester. Feeding difficulties and poor weight gain often manifest in the first months of life. Developmental delays become apparent as expected milestones are delayed or not achieved, typically noticed between six months and two years of age. The long-term prognosis is difficult to generalise given the rarity of the condition and the wide phenotypic spectrum, though supportive care and early intervention therapies can help maximise developmental potential.

Genetic causes

Mosaic trisomy 15 arises from an error in chromosome segregation that occurs after fertilisation, during the early cell divisions of the developing embryo. Unlike inherited chromosomal conditions, this represents a de novo event - a spontaneous mistake in cell division rather than something passed from parent to child. The error results in some cells receiving an extra copy of chromosome 15, creating two distinct cell populations within the same individual: one with the typical 46 chromosomes and another with 47 chromosomes including the additional chromosome 15.

Chromosome 15 carries hundreds of genes involved in diverse biological processes including growth regulation, brain development, and cellular metabolism. When present in three copies rather than two, the genes on this chromosome are expressed at abnormal levels, disrupting the carefully balanced genetic programme that guides normal development. The severity of clinical effects relates to which specific genes are overexpressed and in which tissues the trisomic cells predominate. Research suggests that certain regions of chromosome 15 may be particularly sensitive to dosage imbalance, though the precise mechanisms linking gene overexpression to specific clinical features remain areas of ongoing investigation.

The mosaic pattern means that different tissues may have different proportions of normal and trisomic cells. Blood cells analysed during genetic testing may show one level of mosaicism whilst skin, brain, or other organs harbour different proportions. This tissue-specific variation explains why blood test results cannot always predict clinical severity, as the percentage of abnormal cells in blood may not reflect the situation in developmentally important tissues. Confined placental mosaicism, where the extra chromosome 15 is present in placental cells but not in the foetus itself, is encountered during prenatal testing and requires careful interpretation through additional testing such as amniocentesis.

Inheritance pattern

Mosaic trisomy 15 occurs sporadically and is not inherited from parents in the traditional sense. The chromosomal error happens by chance during the early cell divisions after a genetically normal egg and sperm have united, meaning that parents of an affected child typically have normal chromosomes themselves. This sporadic occurrence pattern means that the recurrence risk for future pregnancies is very low, generally not elevated above the background population risk for chromosomal abnormalities.

Because the condition arises from a random error in early embryonic development rather than being present in the parental germline, siblings of an affected individual are not at increased risk of mosaic trisomy 15 specifically. However, routine pregnancy screening is offered to all expectant parents in the UK regardless of family history, and some families may choose to pursue prenatal diagnostic testing in subsequent pregnancies for reassurance. Genetic counselling can help families understand the sporadic nature of the condition and the very low likelihood of recurrence.

An affected individual with mosaic trisomy 15 theoretically could pass the chromosomal abnormality to their own children if trisomic cells are present in their reproductive tissues, though this depends on the distribution of mosaicism and remains a theoretical rather than frequently observed occurrence given the rarity of the condition. Discussion with a genetic counsellor would be appropriate for affected individuals considering parenthood, to understand their specific situation and any testing options that might be relevant.

Diagnosis & testing

Diagnosis of mosaic trisomy 15 typically occurs through chromosomal analysis, either prenatally or after birth. During pregnancy, the condition may be suspected when ultrasound examinations reveal growth restriction, structural abnormalities, or other features prompting referral for invasive prenatal testing. Chorionic villus sampling or amniocentesis allows collection of foetal cells for karyotype analysis or chromosomal microarray testing, which can identify the presence of an extra chromosome 15 in a proportion of cells examined.

Interpretation of prenatal chromosomal findings requires careful consideration of whether mosaicism represents true foetal involvement or confined placental mosaicism. When chromosome abnormalities are detected in chorionic villus sampling, which samples placental tissue, additional testing through amniocentesis may be recommended to determine whether the foetus itself carries the chromosomal change. This distinction has important implications for prognosis and parental decision-making. After birth, diagnosis may be prompted by clinical features such as growth delay, developmental concerns, or congenital abnormalities, leading to referral for genetic testing. Standard karyotype analysis of blood lymphocytes can detect mosaicism when the abnormal cell line is present at sufficient levels, typically above 5-10 per cent depending on the number of cells analysed, though lower-level mosaicism might be missed and could require analysis of multiple tissues or larger numbers of cells. Chromosomal microarray analysis provides higher resolution and can detect chromosomal imbalances, though standard arrays may not quantify mosaicism as precisely as traditional karyotyping. Within the NHS, clinical genetics services coordinate diagnostic testing following referral from paediatricians, obstetricians, or other specialists. Genetic counsellors play an essential role in explaining test results, discussing clinical implications, and supporting families through the diagnostic process.

UK care pathway

Within the NHS, management of mosaic trisomy 15 involves coordinated care across multiple specialties, tailored to each individual's specific clinical needs. Following diagnosis, referral to clinical genetics services facilitates access to expert genetic counselling, helping families understand the condition, its sporadic nature, and implications for current and future family planning. Genetic counsellors provide ongoing support, particularly valuable given the uncertainty inherent in predicting outcomes for rare chromosomal disorders.

Paediatric follow-up typically includes growth monitoring, developmental assessment, and surveillance for complications such as heart defects or kidney abnormalities. Referrals to relevant specialists - which may include cardiology, nephrology, neurology, or endocrinology - depend on which systems are affected in each individual. Early intervention services including physiotherapy, occupational therapy, and speech and language therapy support developmental progress when delays are identified. Special Educational Needs and Disabilities (SEND) support and, where appropriate, Education, Health and Care Plans (EHCPs) help optimise learning outcomes for children experiencing cognitive or behavioural challenges. The multidisciplinary approach ensures that medical, developmental, and educational needs are addressed comprehensively throughout childhood and into adult services where ongoing needs exist.

Related conditions

Several other chromosomal disorders present with overlapping clinical features that may be considered in the differential diagnosis of mosaic trisomy 15. Other autosomal trisomy mosaics, such as mosaic trisomy 8 (which is more frequently encountered) or mosaic trisomy 9, can cause growth restriction, developmental delays, and variable congenital anomalies, with clinical severity similarly dependent on the level and tissue distribution of mosaicism. Russell-Silver syndrome, a genetic condition characterised by intrauterine and postnatal growth restriction along with body asymmetry, may be considered when growth concerns and asymmetry are prominent features, though this condition typically results from different genetic mechanisms including chromosome 11 abnormalities or imprinting defects.

Uniparental disomy of chromosome 15, where both copies of chromosome 15 are inherited from one parent, can lead to Prader-Willi syndrome or Angelman syndrome depending on which parent contributed both copies, due to imprinting effects on chromosome 15. Whilst the clinical presentations of these imprinting disorders differ substantially from mosaic trisomy 15, they illustrate the sensitivity of chromosome 15 to dosage and parent-of-origin effects. Chromosomal microarray testing and detailed karyotype analysis help distinguish between these various chromosomal causes of developmental delay and growth restriction, guiding appropriate management and genetic counselling.

Frequently asked questions

References

1. Gérard-Blanluet M, Elbez A, Bazin A. Mosaic trisomy 15 and hemihypertrophy. Annales de genetique. 2001. PMID: 11694227
2. Chen CP, Chern SR, Chen YN. Mosaic trisomy 15 at amniocentesis: Prenatal diagnosis, molecular genetic analysis and literature review. Taiwanese journal of obstetrics & gynecology. 2015. PMID: 26384064
3. McPadden J, Helm BM, Spangler BB. Mosaic trisomy 15 in a liveborn infant. American journal of medical genetics. Part A. 2015. PMID: 25736076
4. Trisomy 15 CPM: probable origins, pregnancy outcome and risk of fetal UPD: European Collaborative Research on Mosaicism in CVS (EUCROMIC). Prenatal diagnosis. 1999. PMID: 10073903
5. Chen CP, Hsu TY, Ko TM. Cytogenetic discrepancy between uncultured amniocytes and cultured amniocytes in mosaic trisomy 15 at amniocentesis. Taiwanese journal of obstetrics & gynecology. 2020. PMID: 32917326
6. Redaelli S, Sala E, Roncaglia N. Severe intrauterine growth restriction and trisomy 15 confined placental mosaicism: a case report and review of literature. Prenatal diagnosis. 2005. PMID: 15712378
7. Natacci F, Melloni G, Motta F. Delineating the Mosaic Trisomy 15 Phenotype Using a Serendipitous Mechanism as a Clue. Cytogenetic and genome research. 2015. PMID: 26201389
8. Chen CP, Ko TM, Chen TC. Cytogenetic discrepancy between uncultured amniocytes and cultured amniocytes in mosaic trisomy 15 at amniocentesis in a pregnancy with a favorable outcome. Taiwanese journal of obstetrics & gynecology. 2022. PMID: 35779921